



Abatacept (Orencia)

Provider Order Form rev. 10/12/2022

PATIENT INFORMATION

Referral Status: New Referral Updated Order Order Renewal

Date: _____ Patient Name: _____ DOB: _____

ICD-10 code (required): _____ ICD-10 description: _____

NKDA Allergies: _____ Weight (lbs/kg): _____ Height: _____

Patient Status: New to Therapy Continuing Therapy Last Treatment Date: _____ Next Due Date: _____

PROVIDER INFORMATION

Referral Coordinator Name: _____ Referral Coordinator Email: _____

Ordering Provider: _____ Provider NPI: _____

Referring Practice Name: _____ Phone: _____ Fax: _____

Practice Address: _____ City: _____ State: _____ Zip Code: _____

NURSING

- TB status & date (list results here & attach clinicals)
- Provide nursing care per Nursing Procedures, including reaction management and post-procedure observation

LABORATORY ORDERS

- CBC at each dose every _____
- CMP at each dose every _____
- CRP at each dose every _____
- Other: _____

PRE-MEDICATION ORDERS

- acetaminophen (Tylenol) 500mg / 650mg / 1000mg PO
 - cetirizine (Zyrtec) 10mg PO
 - loratadine (Claritin) 10mg PO
 - diphenhydramine (Benadryl) 25mg / 50mg PO / IV
 - methylprednisolone (Solu-Medrol) 40mg / 125mg IV
 - hydrocortisone (Solu-Cortef) 100mg IV
 - Other: _____
- Dose: _____ Route: _____
- Frequency: _____

THERAPY ADMINISTRATION

- Abatacept** (Orencia) in 100ml 0.9% sodium chloride, intravenous infusion over 30 minutes (use in line filter 0.2 to 1.2 micron)
 - Dose: 500mg / 750mg / 1000mg / _____mg
 - Frequency: induction: week 0, 2, and 4, then every 4 weeks / maintenance: every 4 weeks / other: _____
- Route: intravenous
- Infuse over 30 minutes
- Remove equal volume from bag prior to adding medication
- Flush with 0.9% sodium chloride at infusion completion
- Abatacept** (Orencia) injection
 - Dose: 50mg / 87.5mg / 125mg
 - Frequency: weekly / other: _____
 - Route: subcutaneous
- Patient is required to stay for 30-minute observation
- Refills: Zero / for 12 months / _____ (if not indicated order will expire one year from date signed)

SPECIAL INSTRUCTIONS

Screen for latent TB infection prior to initiating therapy. Patients testing positive should be treated prior to initiating ORENCIA.

Provider Name (Print) _____ Provider Signature _____ Date _____

Please include the following information when submitting a referral for Orencia:

- *Patient's current weight and height
- *Clinicals to support one or more of the following:
- *Patient has rheumatoid arthritis (RA)
- *Patient has juvenile idiopathic arthritis (JIA)
- *Patient has psoriatic arthritis